CryoPort supported 779 clinical trials globally at the end of the quarter, up by a net 51 trials from the prior year. Shelton said the company supports approximately 70% of clinical trials in the cell and gene therapy industry. During the second quarter, CryoPort added 29 clinical trials and removed 16, according to Vice President of Corporate Development and Investor Relations Thomas Heinzen. Shelton said CryoPort considered it prudent to retain the existing outlook because of geopolitical and macroeconomic uncertainties. About CryoPort (NASDAQ:CYRX)CryoPort, Inc (NASDAQ: CYRX) is a global provider of temperature-controlled logistics solutions for the life sciences industry.